Compare Stocks: LTRN, CBUS, PMN, and ADCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$0.97 -3.1%	$1.14	$0.78 ▼ $4.98	$123.33M	1.89	1.30 million shs	640,512 shs
CBUS Cibus	$1.73 +1.8%	$1.71	$1.09 ▼ $4.19	$132.22M	1.61	442,052 shs	116,171 shs
LTRN Lantern Pharma	$2.11 -9.8%	$3.17	$1.11 ▼ $4.70	$26.97M	2.34	326,421 shs	150,823 shs
PMN Promis Neurosciences	$14.80 +2.0%	$13.21	$6.27 ▼ $27.40	$132.76M	-0.23	106,907 shs	38,558 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-0.76%	-15.11%	-70.62%	-68.49%
CBUS Cibus	0.00%	-3.95%	0.00%	+23.19%	+24.09%
LTRN Lantern Pharma	0.00%	-11.70%	-14.91%	-33.14%	-48.12%
PMN Promis Neurosciences	0.00%	-2.36%	+18.93%	+32.15%	+8.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$0.97 -3.1%	$1.14	$0.78 ▼ $4.98	$123.33M	1.89	1.30 million shs	640,512 shs
CBUS Cibus	$1.73 +1.8%	$1.71	$1.09 ▼ $4.19	$132.22M	1.61	442,052 shs	116,171 shs
LTRN Lantern Pharma	$2.11 -9.8%	$3.17	$1.11 ▼ $4.70	$26.97M	2.34	326,421 shs	150,823 shs
PMN Promis Neurosciences	$14.80 +2.0%	$13.21	$6.27 ▼ $27.40	$132.76M	-0.23	106,907 shs	38,558 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-0.76%	-15.11%	-70.62%	-68.49%
CBUS Cibus	0.00%	-3.95%	0.00%	+23.19%	+24.09%
LTRN Lantern Pharma	0.00%	-11.70%	-14.91%	-33.14%	-48.12%
PMN Promis Neurosciences	0.00%	-2.36%	+18.93%	+32.15%	+8.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	417.60% Upside
CBUS Cibus	2.00	Hold	$9.00	420.23% Upside
LTRN Lantern Pharma	1.00	Sell	N/A	N/A
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	129.73% Upside

Current Analyst Ratings Breakdown

Latest LTRN, CBUS, PMN, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/14/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/7/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$79.58M	1.55	N/A	N/A	($1.50) per share	-0.64
CBUS Cibus	$4.35M	30.42	N/A	N/A	$0.40 per share	4.33
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$0.58 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
CBUS Cibus	-$127.08M	-$1.65	N/A	N/A	N/A	-2,258.89%	-287.03%	-27.99%	11/12/2026 (Estimated)
LTRN Lantern Pharma	-$17.12M	-$1.62	N/A	N/A	N/A	N/A	-368.02%	-148.62%	11/11/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)

Latest LTRN, CBUS, PMN, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	-$0.57	-$0.19	-$0.57	N/A	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	CBUS Cibus	-$0.19	-$0.29	-$0.10	-$0.29	$1.70 million	$0.99 million
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CBUS Cibus	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
CBUS Cibus	N/A	1.62	1.62
LTRN Lantern Pharma	N/A	1.96	1.96
PMN Promis Neurosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CBUS Cibus	33.81%
LTRN Lantern Pharma	28.62%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
CBUS Cibus	29.91%
LTRN Lantern Pharma	8.50%
PMN Promis Neurosciences	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.67 million	121.16 million	Optionable
CBUS Cibus	48	76.43 million	53.57 million	Optionable
LTRN Lantern Pharma	20	12.78 million	11.70 million	Optionable
PMN Promis Neurosciences	5	8.97 million	8.83 million	Not Optionable

LTRN, CBUS, PMN, and ADCT Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)

August 22 at 6:10 AM | theglobeandmail.com

PMN Q3 EPS Forecast Boosted by Brookline Capital Markets

August 21 at 2:03 AM | americanbankingnews.com

Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

August 19, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

August 14, 2026 | marketbeat.com

Promis Neurosciences Q2 Earnings Call Highlights

August 13, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 13, 2026 | marketbeat.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | finanznachrichten.de

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | globenewswire.com

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 7, 2026 | marketbeat.com

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

August 6, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN

August 4, 2026 | marketbeat.com

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum

August 4, 2026 | gurufocus.com

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 3, 2026 | globenewswire.com

ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN

July 30, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital

July 29, 2026 | marketbeat.com

Yu Fan Buys New Stake in Promis Neurosciences $PMN

July 29, 2026 | marketbeat.com

Promis Neurosciences $PMN Stock Holdings Boosted by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data

July 28, 2026 | marketbeat.com

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

July 28, 2026 | benzinga.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026 | markets.businessinsider.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

July 28, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN, CBUS, PMN, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$0.97 -0.03 (-3.07%)

Closing price 03:59 PM Eastern

Extended Trading

$0.97 +0.00 (+0.21%)

As of 04:51 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Cibus NASDAQ:CBUS

$1.73 +0.03 (+1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 -0.05 (-3.12%)

As of 05:14 PM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Lantern Pharma NASDAQ:LTRN

$2.11 -0.23 (-9.83%)

Closing price 04:00 PM Eastern

Extended Trading

$2.16 +0.05 (+2.42%)

As of 06:41 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Promis Neurosciences NASDAQ:PMN

$14.80 +0.29 (+2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$14.86 +0.06 (+0.41%)

As of 04:10 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LTRN, CBUS, PMN, and ADCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LTRN, CBUS, PMN, and ADCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LTRN, CBUS, PMN, and ADCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN, CBUS, PMN, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

Cibus NASDAQ:CBUS

Lantern Pharma NASDAQ:LTRN

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LTRN, CBUS, PMN, and ADCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LTRN, CBUS, PMN, and ADCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LTRN, CBUS, PMN, and ADCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN, CBUS, PMN, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

Cibus NASDAQ:CBUS

Lantern Pharma NASDAQ:LTRN

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools